Skip Navigation

European Heart Journal 2004 25(17):1475-1476; doi:10.1016/j.ehj.2004.07.015
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Messerli, F. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Messerli, F. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

TIMPs, MMPs and cardiovascular disease

Franz H. Messerli*

Ochsner Clinic Foundation, New Orleans, Louisiana, USA

* Correspondence to: Franz H. Messerli, M.D., Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA. Tel.: +1 504 842 3144; fax: +1 504 842 4220 (E-mail: fmesserli@aol.com).

The first 10% of the full text of this article appears below.

This editorial refers to "Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study"{dagger} by J. Sundstrรถm et al. on page 1509

The matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that cleave the extracellular matrix and have been shown to be regulated by a class of proteins called the tissue inhibitors of metalloproteinases (TIMPs). Several studies have shown that extracellular matrix degradation by MMPs, specifically MMP-9, is involved in the pathogenesis of a wide spectrum of cardiovascular disorders, including atherosclerosis, restenosis, cardiomyopathy, congestive . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study
Johan Sundström, Jane C. Evans, Emelia J. Benjamin, Daniel Levy, Martin G. Larson, Douglas B. Sawyer, Deborah A. Siwik, Wilson S. Colucci, Peter W.F. Wilson, and Ramachandran S. Vasan
EHJ 2004 25: 1509-1516. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S. Zibadi, R. Vazquez, D. Moore, D. F. Larson, and R. R. Watson
Myocardial lysyl oxidase regulation of cardiac remodeling in a murine model of diet-induced metabolic syndrome
Am J Physiol Heart Circ Physiol, September 1, 2009; 297(3): H976 - H982.
[Abstract] [Full Text] [PDF]